In this issue:
Australia’s capacity to treat HCV with IFN-free regimens
Elbasvir/grazoprevir and compensated cirrhosis
Retreating HCV after DAA-based therapies fail
Glecaprevir + pibrentasvir looks promising in HCV GT 1–6
Improvement in portal pressure after SVR
Elbasvir/grazoprevir + ribavirin: suboptimal efficacy in HCV GT 3
Risk of preterm birth in women with HBV infection
Point-of-care testing for HCV – are we nearly there?
Ombitasvir, paritaprevir, ritonavir + dasabuvir for 8 weeks in HCV GT 1b
An analysis of HCV reinfection risk
Please login below to download this issue (PDF)